Myopathies inflammatoires
Veille bibliographique : Myopathies inflammatoires
Les articles sont classés du plus ancien au plus récent, n’hésitez pas à utiliser la barre de recherche pour filtrer les résultats par date par exemple.
| Dieval C et al. Myocarditis in Patients With Antisynthetase Syndrome: Prevalence, Presentation, and Outcomes Medicine (Baltimore). 2015 Jul;94(26):e798. | Lire le résumé |
| Ruperto N et al. Paediatric Rheumatology International Trials Organisation (PRINTO). Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juveniledermatomyositis: a randomised trial. Lancet. 2015 Nov 27. | Lire le résumé |
| Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med. juill 2016;280(1):24‑38. | Lire le résumé |
| Habers GEA et al. Muscles in motion: a randomized controlled trial on the feasibility, safety and efficacy of an exercise training programme in children and adolescents with juvenile dermatomyositis. Rheumatol Oxf Engl. juill 2016;55(7):1251‑62. | Lire le résumé |
| Pinal-Fernandez I et al. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis. 20 sept 2016 | Lire le résumé |
| Deakin CT et al. UK Juvenile Dermatomyositis Research Group. Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis. Arthritis Rheumatol. 2016 Nov;68(11):2806-2816. 2016 Oct 9. | Lire le résumé |
| Uruha A et al. Sarcoplasmic MxA expression: A valuable marker of dermatomyositis. Neurology. 2016 Dec 30. | Lire le résumé |
| Arouche-Delaperche Louiza et al. Pathogenic Role of Anti-SRP and Anti-HMGCR Antibodies in Necrotizing Myopathies: Myofiber Atrophy and Impairment of Muscle Regeneration in Necrotizing Autoimmune Myopathies. Annals of Neurology, February 22, 2017. | Lire le résumé |
| Aggarwal R et al. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. mai 2017;76(5):792‐801. | Lire le résumé |
| Mamyrova G et al. Environmental factors associated with disease flare in juvenile and adult dermatomyositis.Rheumatology (Oxford). 2017 Apr 21. | Lire le résumé |
| Bachasson D et al. Physical Activity Monitoring: A Promising Outcome Measure in Idiopathic Inflammatory Myopathies. Neurology. 2017 May 31 | Lire le résumé |
| Meyer A et al. IFN-β-induced reactive oxygen species and mitochondrial damage contribute to muscle impairment and inflammation maintenance in dermatomyositis. Acta Neuropathol (Berl). 2017 Jun 16 | Lire le résumé |
| Suzuki S et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 18 août 2017 | Lire le résumé |
| Lilleker JB et al. The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis. 2017 Aug 30 | Lire le résumé |
| Lundberg IE et al. 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis Rheumatol Hoboken NJ. 2017 Oct 27 | Lire le résumé |
| Varnier GC. et al. Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care. Arthritis Care Res (Hoboken). 2017 Dec 15. | Lire le résumé |
| Allenbach Y. et al. Necrosis in anti-SRP+ and anti-HMGCR+myopathies: Role of autoantibodies and complement. Neurology. 2018 Jan 12. | Lire le résumé |
| Silverberg JI et al. Cardiovascular and cerebrovascular comorbidities of juvenile dermatomyositis in US children: an analysis of the National Inpatient Sample. Rheumatology (Oxford). 2018 Jan 24. | Lire le résumé |
| Aouizerate J, De Anton io M et al. Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis.. Rheumatology (Oxford). 2018 Feb 20 | Lire le résumé |
| Yeker RM, Pinal-Fernandez I, Kishi T, Pak K, Targoff IN, Miller FW, et al. Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis. Annals of the Rheumatic Diseases, 2018 May 7 | Lire le résumé |
| Ladislau L, Suárez-Calvet X, Toquet S, Landon-Cardinal O, Amelin D, Depp M, et al. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain. 2018 Jun 1;141(6):1609–21 | Lire le résumé |
| Thyoka M, Adekunle O, Pilkington C, Walters S, Arthurs OJ, Humphries P, et al. Introduction of a novel magnetic resonance imaging-based scoring system for assessing disease activity in children with juvenile dermatomyositis. Rheumatology [Internet]. 2018 Jun 12 [cited 2018 Jul 27]; | Lire le résumé |
| Touat M, Maisonobe T, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology. 2018 Aug 8 | Lire le résumé |
| Touat M, Maisonobe T, Knauss S, Ben Hadj Salem O, Hervier B, Auré K, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology. 2018 Sep 4;91(10):e985– 94 | Lire le résumé |
| Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F, et al. Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies. JAMA Neurology [Internet]. 2018 Sep 10 [cited 2018 Sep 25] | Lire le résumé |
| Kubo S, Todoroki Y, Nakayamada S, Nakano K, Satoh M, Nawata A, et al. Significance of nailfold videocapillaroscopy in patients with idiopathic inflammatory myopathies. Rheumatology (Oxford). 2018 Aug 28; | Lire le résumé |
| Mamyrova G, Kishi T, Targoff IN, Ehrlich A, Curiel RV, Rider LG, et al. Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis. Rheumatology. 2018 Nov 1;57(11):1956–63. | Lire le résumé |
| Bergua C, Chiavelli H, Allenbach Y, Arouche-Delaperche L, Arnoult C, Bourdenet G, et al. In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Annals of the Rheumatic Diseases. 2018 Oct 11;annrheumdis-2018-213518. | Lire le résumé |
| Takanashi S, Nishina N, Nakazawa M, Kaneko Y, Takeuchi T. Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease. Rheumatology [Internet]. 2019 Jan 8 [cited 2019 Jan 22]; Available from: https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/key420/5280963 | Lire le résumé |
| Pinal-Fernandez I, Amici DR, Parks CA, Derfoul A, Casal-Dominguez M, Pak K, et al. Myositis autoantigen expression correlates with muscle regeneration but not autoantibody specificity. Arthritis Rheumatol [Internet]. 12 mars 2019 [cité 26 mars 2019]; Disponible sur: http://doi.wiley.com/10.1002/art.40883 | Lire le résumé |
| Matuszak J, Blondet C, Hubelé F, Gottenberg J-E, Sibilia J, Bund C, et al. Muscle fluorodeoxyglucose uptake assessed by positron emission tomography–computed tomography as a biomarker of inflammatory myopathies disease activity. Rheumatology [Internet]. 8 mars 2019 [cité 24 avr 2019]; Disponible sur: https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/kez040/5372754 | Lire le résumé |
| Aussy A, Fréret M, Gallay L, Bessis D, Vincent T, Jullien D, et al. The IgG2 isotype of anti‐transcription intermediary factor 1‐gamma autoantibodies is a biomarker of mortality in adult dermatomyositis. Arthritis Rheumatol [Internet]. 21 mars 2019 [cité 28 mai 2019]; Disponible sur: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.40895 | Lire le résumé |
| Salem J-E, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, et al. Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis. N Engl J Med. 13 juin 2019;380(24):2377 9 | Lire le résumé |
| Chen Z, Wang X, Ye S. Tofacitinib in Amyopathic Dermatomyositis–Associated Interstitial Lung Disease. N Engl J Med. 18 juill 2019;381(3):291 3 | Lire le résumé |
| Melki I, Devilliers H, Gitiaux C, Bondet V, Duffy D, Charuel J-L, et al. Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-α signalling. Rheumatology [Internet]. 22 nov 2019 [cité 20 déc 2019] | Lire le résumé |
| Tansley SL, Li D, Betteridge ZE, McHugh NJ. The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity. Rheumatology [Internet]. 6 févr 2020 [cité 25 févr 2020]; | Lire le résumé |
| Chung MP, Richardson C, Kirakossian D, Orandi AB, Saketkoo LA, Rider LG, et al. Calcinosis Biomarkers in Adult and Juvenile Dermatomyositis. Autoimmun Rev. mars 2020;102533 | Lire le résumé |
| Monseau G, Landon-Cardinal O, Stenzel W, Schoindre Y, Mariampillai K, Barete S, et al. Systematic retrospective study on 64 patients anti-Mi2 dermatomyositis: a classic skin rash with a necrotizing myositis and high risk of malignancy. J Am Acad Dermatol. mars 2020;S0190962220304801 | Lire le résumé |
| for the Juvenile Dermatomyositis Research Group (JDRG), Campanilho-Marques R, Deakin CT, Simou S, Papadopoulou C, Wedderburn LR, et al. Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients. Arthritis Res Ther [Internet]. déc 2020 [cité 22 juin 2020];22(1). | Lire le résumé |
| McElhanon KE, Young N, Hampton J, Paleo BJ, Kwiatkowski TA, Beck EX, et al. Autoantibodies targeting TRIM72 compromise membrane repair and contribute to inflammatory myopathy. J Clin Invest [Internet]. 20 juill 2020 [cité 31 juill 2020] | Lire le résumé |
| Felten R, Giannini M, Nespola B, Lannes B, Levy D, Seror R, et al. Refining myositis associated with primary Sjögren’s syndrome: data from the prospective cohort ASSESS. Rheumatology [Internet]. 11 août 2020 [cité 27 août 2020] | Lire le résumé |
| Kim H, Gunter-Rahman F, McGrath JA, Lee E, de Jesus AA, Targoff IN, et al. Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. Arthritis Res Ther [Internet]. déc 2020 [cité 16 sept 2020];22(1) | Lire le résumé |
| Sugiyama Y, Yoshimi R, Takeno M, Kunishita Y, Kishimoto D, Kamiyama R, et al. miR-1 is a novel biomarker for polymyositis/dermatomyositis-associated interstitial lung disease. Mod Rheumatol. 2 sept 2020;30(5):878‑83. | Lire le résumé |
| Landon-Cardinal O, Baril-Dionne A, Hoa S, Meyer A, Leclair V, Bourré-Tessier J, et al. Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies. RMD Open. sept 2020;6(2):e001357. | Lire le résumé |
| Langlois V, Gillibert A, Uzunhan Y, Chabi M-L, Hachulla E, Landon-Cardinal O, et al. Rituximab and Cyclophosphamide in Antisynthetase Syndrome–related Interstitial Lung Disease: An Observational Retrospective Study. J Rheumatol. 1 nov 2020;47(11):1678‑86. | Lire le résumé |
| Papadopoulou C, Hong Y, Krol P, Al Obaidi M, Pilkington C, Wedderburn LR, et al. The Vasculopathy of Juvenile Dermatomyositis: endothelial injury, hypercoagulability, and increased arterial stiffness. Arthritis Rheumatol [Internet]. 4 janv 2021 [cité 26 janv 2021] | Lire le résumé |
| Le Voyer T, Gitiaux C, Authier F-J, Bodemer C, Melki I, Quartier P, et al. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. Rheumatology [Internet]. 12 févr 2021 [cité 22 mars 2021]; | Lire le résumé |
| Levy D, Nespola B, Giannini M, Felten R, Severac F, Varoquier C, et al. Significance of Sjögren’s syndrome and anti-cN1A antibody in myositis patients. Rheumatology [Internet]. 11 mai 2021 [cité 28 mai 2021]; | Lire le résumé |
| 1. Siegert E, Uruha A, Goebel H-H, Preuße C, Casteleyn V, Kleefeld F, et al. Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology. Acta Neuropathol (Berl). juin 2021;141(6):917‑27. 2. Ellezam B, Leclair V, Troyanov Y, Meyer A, Hudson M, Landon-Cardinal O. Capillary basement membrane reduplication in myositis patients with mild clinical features of systemic sclerosis supports the concept of ‘scleromyositis’. Acta Neuropathol (Berl). août 2021;142(2):395‑7. " | Lire le résumé |
| Huang L, Fu Q, Ye Y, Lin Y, Yan Q, Chen S. High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibody-positive dermatomyositis: experience from a single center. Arthritis Res Ther. déc 2021;23(1):232. | Lire le résumé |
| Laporte A, Mariampillai K, Allenbach Y, Pasi N, Donciu V, Toledano D, et al. Idiopathic inflammatory myopathies: CT characteristics of interstitial lung disease and their association(s) with myositis-specific autoantibodies. Eur Radiol [Internet]. 13 janv 2022 [cité 28 janv 2022]; | Lire le résumé |
| Wang L-M, Yang Q-H, Zhang L, Liu S-Y, Zhang P-P, Zhang X, et al. Intravenous immunoglobulin for interstitial lung diseases of anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Rheumatol Oxf Engl. 23 déc 2021;keab928. | Lire le résumé |
| Gallay L, Fermon C, Lessard L, Weiss-Gayet M, Viel S, Streichenberger N, et al. Involvement of Type I Interferon Signaling in Muscle Stem Cell Proliferation During Dermatomyositis. Neurology. 24 mai 2022;98(21):e2108‐19 | Lire le résumé |
| Matas-García A, Guillén-Del-Castillo A, Kisluk B, Selva-O’Callaghan A, Espinosa G, Prieto-González S, et al. Clinico-pathological phenotypes of Systemic Sclerosis associated myopathy: analysis of a multicenter large cohort. Rheumatology. 17 juin 2022;keac361 | Lire le résumé |
| Topilow JS, Ospina Cardona D, Beck DB, Ferrada MA, McMahan ZH, Paik JJ. Novel genetic mutation in myositis-variant of VEXAS syndrome. Rheumatology. 17 juin 2022;keac356 | Lire le résumé |
| Rivière A, Picard C, Berastegui C, Mora VM, Bunel V, Godinas L, et al. Lung transplantation for interstitial lung disease in idiopathic inflammatory myositis: A cohort study. Am J Transplant. 3 sept 2022;ajt.17177 | Lire le résumé |
| Aggarwal R, Charles-Schoeman C, Schessl J, Bata-Csörgő Z, Dimachkie MM, Griger Z, et al. Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med. 6 oct 2022;387(14):1264‐78 | Lire le résumé |
| Bader-Meunier B, Breton S, Duffy D, Gitiaux C, Quartier P, Lemelle I, et al. Osteonecrosis in patients with juvenile dermatomyositis: is it associated with anti-MDA5 autoantibody? Rheumatology. 2 janv 2023;keac696 | Lire le résumé |
| Mammen AL, Amato AA, Dimachkie MM, Chinoy H, Hussain Y, Lilleker JB, et al. Zilucoplan in immunemediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial. Lancet Rheumatol. févr 2023;5(2):e67‑76. | Lire le résumé |